COMMUNIQUÉS West-GlobeNewswire

CHMP Recommends Zynquista™ (Sotagliflozin) for the Treatment of Adults With Type 1 Diabetes
01/03/2019
PARIS and THE WOODLANDS, Texas, March 01, 2019 (GLOBE NEWSWIRE) -- The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Marketing Authorization of [...]
Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
01/03/2019
First and only therapy approved for FCS, a serious and rare disease with no approved treatment options BOSTON, Mass. and CARLSBAD, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an [...]
European CHMP Adopts Positive Opinion on Ondexxya™ (andexanet alfa) Portola Pharmaceuticals’ Factor Xa Inhibitor Reversal Agent
01/03/2019
SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines [...]
Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results
01/03/2019
SAN DIEGO, March 01, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31, 2018, after the [...]
TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting
01/03/2019
Annualized Relapse Rate (ARR) of 0.07 observed for all patients on Phase 2 MS trial NEW YORK, March 01, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing [...]
Wave Life Sciences Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Business Update
01/03/2019
Outlines plans for building a fully integrated genetic medicines company CAMBRIDGE, Mass., March 01, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed [...]
Expert Dermatologists Present Latest Information at 2019 AAD Annual Meeting
01/03/2019
WASHINGTON, March 01, 2019 (GLOBE NEWSWIRE) -- The 2019 American Academy of Dermatology Annual Meeting will take place March 1-5 at the Walter E. Washington Convention Center in Washington. The meeting will feature the [...]
Mithra Reports 2018 Annual Results
01/03/2019
Mithra Reports 2018 Annual Results Strong revenue growth (+42%) with significantly improved EBITDA (record level of EUR 38.3 M vs. EUR -18.4 M in 2017) and cash position (EUR 119 M vs. EUR 36.2 M in 2017) thanks to [...]
Mithra annonce ses résultats annuels 2018
01/03/2019
Mithra annonce ses résultats annuels 2018 Forte croissance du chiffre d'affaires (+42%) et amélioration significative de l'EBITDA qui atteint un niveau record (38,3 millions EUR contre -18,4 millions EUR en 2017) tout [...]
Sport Endurance Enters into Definitive Agreements to Acquire TruPet and Bona Vida
01/03/2019
BROOKLYN, N.Y., March 01, 2019 (GLOBE NEWSWIRE) -- Sport Endurance, Inc. (OTCQB: SENZ) (the “Company”), to be reincorporated as Better Choice Company, Inc., today announced entering into definitive agreements to acquire [...]
Mersana Therapeutics Announces Pricing of Public Offering of Common Stock
01/03/2019
CAMBRIDGE, Mass., March 01, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates ( [...]
ChromaDex to Present at the 39th Annual Cowen Health Care Conference
01/03/2019
LOS ANGELES, March 01, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 39 th Annual Cowen [...]
Dentsply Sirona Reports Preliminary Fourth Quarter and Full Year 2018 Results
01/03/2019
Reported Q4 revenues of $1,059.7 million, down 2.9%, and down 0.1% on an internal sales growth basis. [1] Q4 2018 US GAAP EPS of $0.01 vs. a loss of $2.85 in Q4 2017. Q4 2018 Non-US GAAP EPS of $0.58 compared with Non- [...]
Digirad Corporation Reports Financial Results for the Fourth Quarter and Twelve Months Ended December 31, 2018
01/03/2019
Performs within guidance for Revenue and Free Cash Flow for 2018 Pays down $10 million in debt during 2018, including $4 million in Q4 2018 SUWANEE, Ga., March 01, 2019 (GLOBE NEWSWIRE) -- Digirad Corporation (Nasdaq: [...]
Oasmia Pharmaceutical AB (publ)
01/03/2019
Interim report for the period May 2018 – January 2019 THIRD QUARTER November 1, 2018 – January 31, 2019 Consolidated net sales amounted to TSEK 1,427 compared to TSEK 656 in the third quarter the previous year Operating [...]
DBV Technologies to Attend Upcoming Investor Conferences
01/03/2019
Montrouge, France, March 1, 2019 DBV Technologies to Attend Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, [...]
DBV Technologies invitée à présenter lors de prochaines conférences Investisseurs
01/03/2019
Montrouge, France, le 1 mars (7h30 CET), 2019 DBV Technologies invitée à présenter lors de prochaines conférences Investisseurs DBV Technologies (Euronext: DBV – ISIN : FR0010417345 - Nasdaq Stock Market : DBVT), une [...]
Kiadis Pharma to present at upcoming investor conferences in March 2019
01/03/2019
Kiadis Pharma to present at upcoming investor conferences in March 2019 Amsterdam, The Netherlands, March 1, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a [...]
Orphazyme announces Annual Report 2018
01/03/2019
Orphazyme A/S Company announcement No. 04/2019 Company Registration No. 32266355 Copenhagen, Denmark, March 1, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for [...]

Pages